Physician profile
Ashraf Al-Dadah
NPI 1457526576
$5,192.54
in general payments reported to CMS, 2019-2025
21 companies · $243 in 2025
The $243 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $615 · 2020: $446 · 2021: $2,000 · 2022: $616 · 2023: $821 · 2024: $452 · 2025: $243.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,515.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,515.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,063.43 | 2021-2023 | Corevalve Evolut R |
| Abbott Laboratories | $430.71 | 2021-2025 | Pressurewire, Jot Dx, Thoratec Heartmate 3 Lvas Implant Kit |
| Janssen Pharmaceuticals, INC | $338.38 | 2019-2021 | |
| Impulse Dynamics (USA) INC. | $280.74 | 2021-2023 | Optimizer |
| Biotronik INC. | $247.38 | 2021-2022 | |
| Boston Scientific Corporation | $244.53 | 2019-2023 | Watchman Access System |
| Biosense Webster, INC. | $231.71 | 2019-2020 | |
| Bard Peripheral Vascular, INC. | $211.56 | 2019-2023 | |
| Shockwave Medical, INC | $206.66 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Cardiva Medical, INC. | $160.08 | 2024-2025 | Cardiva Vascade Mvp Vvcs 6-12f |
| Penumbra, INC. | $158.50 | 2022 | |
| Pfizer INC. | $125.00 | 2020 | |
| Scpharmaceuticals INC. | $125.00 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $95.33 | 2019-2023 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.65 | 2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $73.95 | 2019 | |
| Cardiovascular Systems INC. | $36.91 | 2019-2021 | |
| Endologix LLC | $35.71 | 2025 | Afx2 Bifurcated Endograft System |
| Abiomed | $31.71 | 2019 | |
| Philips North America LLC | $12.60 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashraf Al-Dadah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.